Avalo Therapeutics (AVTX) Finished Goods (2017 - 2019)

Avalo Therapeutics has reported Finished Goods for 3 years, with the latest figure at $46705.0 in Q4 2019.

• For the quarter ending Q4 2019, Finished Goods fell 90.62% year-over-year to $46705.0; the trailing twelve-month figure through Dec 2019 stood at $46705.0 (down 90.62% YoY), and the FY2019 full-year result was $46705.0, down 90.62% from the prior year.
• Finished Goods for Q4 2019 stood at $46705.0, down from $497949.0 in the prior quarter.
• The five-year high for Finished Goods was $560499.0 in Q4 2017, with the low at $46705.0 in Q4 2019.
• Historically, Finished Goods has averaged $368384.3 across 3 years, with a median of $497949.0 in 2018.
• Annual changes were most pronounced in 2018 — Finished Goods slipped 11.16% — and 2019, when it tumbled 90.62%.
• Avalo Therapeutics' Finished Goods stood at $560499.0 in 2017, then decreased by 11.16% to $497949.0 in 2018, then plunged by 90.62% to $46705.0 in 2019.
• The last three Finished Goods figures came in at $46705.0 (Q4 2019), $497949.0 (Q4 2018), and $560499.0 (Q4 2017), per Business Quant data.